BioSim strengthens its national representation with the incorporation of ROVI Pharmaceutical Laboratories
ROVI joins BioSim to strengthen initiatives that promote greater access to and knowledge about biosimilar medicines.
ROVI reports operating revenue growth of 26% and EBITDA growth of 37%
ROVI has now filed the final responses to the Complete Response Letter received from the United States Food and Drug Administration (FDA) in the third quarter of 2022
The Minister, Alexandru Rafila, was accompanied by the Director of Cabinet of the Romanian Ministry of Health and the Romanian Ambassador to Spain.